H.C. Wainwright analyst Corey Davis initiated Antares Pharma with a Buy and a $5 price target saying he sees further upside as its diversified business strategy finally matures in the near future. The analyst said Antares is a sum-of-the-parts story, and we believe several of those parts could come into clarity within months, including potential 3Q17 A/B-rated generic EpiPen approval, Antares' own Xyosted testosterone PDUFA date, Oct. 2017, partnered generic Byetta approval/launch, and partnered Makena auto injector Oct. 2017 PDUFA. Davis expects cash flow to breakeven in second half 2018, profitability in 2019, and said sum-of-the parts valuation results in a $5 price target.